Related Experiment Video

Updated: May 27, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical

Helen Vosper1

  • 1School of Pharmacy and Life Sciences, Robert Gordon University, Schoolhill, Aberdeen, AB10 1FR, Scotland, UK.

Clinical Medicine Insights. Cardiology
|November 16, 2011
PubMed

Insights

Extended-release niacin with laropiprant offers an effective strategy for managing hypercholesterolemia and mixed dyslipidemias. This combination addresses low HDL-C and high TGs, improving cardiovascular risk factors.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Atherosclerosis progression is a significant cause of mortality, driven by immunological responses to risk factors.
  • Statins effectively reduce LDL-C but offer limited risk reduction; other factors like low HDL-C and high TGs are crucial.
  • Niacin normalizes HDL-C but is underutilized due to flushing side effects.

Purpose of the Study:

  • To review the clinical efficacy of extended-release niacin combined with laropiprant.
  • To evaluate this combination therapy for hypercholesterolemia and mixed dyslipidemias.

Main Methods:

  • Review of clinical evidence on extended-release niacin and laropiprant.
  • Analysis of treatment outcomes for hypercholesterolemia and mixed dyslipidemias.

Main Results:

  • Extended-release niacin is effective in normalizing HDL-C.
  • Laropiprant, a DP1 antagonist, mitigates niacin-induced flushing.
  • The combination demonstrates clinical efficacy in managing lipid profiles.

Conclusions:

  • Extended-release niacin and laropiprant offer a promising therapeutic option.
  • This combination addresses key lipid targets and improves treatment tolerability.
  • It represents an important advancement in managing dyslipidemias and cardiovascular risk.

Keywords:
DP1 receptoratherosclerosisextended-release niacinflushinglaropiprantprostaglandin D2

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Modified-Release Drug Delivery Systems: Influencing Factors01:20

Modified-Release Drug Delivery Systems: Influencing Factors

Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...